The purpose of this study was to determine the safety and
efficacy of botulinum toxin type A (BOTOX; Allergan, Irvine,
USA) in migraine prophylaxis. We performed a double-blind,
randomized, 90-day placebo-controlled study that enrolled 30
adult migraineurs. Patients received 50 units botulinum toxin
type A (n=15) or placebo (n=15). Outcome measures were monthly
frequency and duration of migraine attacks and the number of
severe attacks. Botulinum toxin type A produced significantly
greater reductions in the frequency of migraine attacks of any
severity at Day 90 (-3.14 vs. -0.53;
p
<0.05) and in the frequency of
severe migraine attacks at Days 60 (-1.4 vs. -0.54;
p
<0.05) and 90 (-1.8 vs.
-0.20;
p
<0.02). One
patient in the botulinum toxin type A group experienced mild,
transient frontalis muscle weakness lasting approximately 30
days. Botulinum toxin type A injections were well tolerated and
provided effective migraine prophylaxis in these
patients.
Chronic migraine is a condition with significant prevalence all around the world and high socioeconomic impact, and its handling has been challenging neurologists. Developments for understanding its mechanisms and associated conditions, as well as that of new therapies, have been quick and important, a fact which has motivated the Latin American and Brazilian Headache Societies to prepare the present consensus. The treatment of chronic migraine should always be preceded by a careful diagnosis review; the detection of possible worsening factors and associated conditions; the stratification of seriousness/impossibility to treat; and monitoring establishment, with a pain diary. The present consensus deals with pharmacological and nonpharmacological forms of treatment to be used in chronic migraine.
Familial amyloidotic polyneuropathy type I is an autosomal dominant inherited disorder characterized by progressive peripheral and autonomic neuropathy, associated with neural and systemic amyloid deposits. The abnormality usually lies in the transthyretin (TTR) gene. We report a 25 years old man with 18 months history of dysesthesias and pain in the toes, abnormal micturition and sexual dysfunction. Neurophysiologically studies disclosed a sensory-motor axonal polyneuropathy. Autonomic tests showed sympathetic and parasympathetic involvement. An electron micrograph of sural nerve revealed amyloid fibrils in the endoneurium. His mother died after a clinical history suggestive, in retrospect, of familial amyloidotic polyneuropathy type I. The clinical and genetic analysis of this cause of polyneuropathy are discussed (Rev Méd Chile 2003; 131: 1179-82). (Recibido el 30 de abril, 2003. Aceptado en versión corregida el 25 de agosto, 2003.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.